Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
Status:
Withdrawn
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute
Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of
prednisone for treatment of drug-induced AIN. Currently there is no good treatment for
drug-induced AIN. Prednisone is the standard treatment but is associated with many
side-effects when used long-term and at high doses.